scholarly journals RE: Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer

2013 ◽  
Vol 106 (2) ◽  
pp. djt370-djt370 ◽  
Author(s):  
L. M. Hess ◽  
G. Carter ◽  
L. Smolen ◽  
L. Bowman ◽  
P. von Hohnhorst ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Metastatic Colorectal Cancer ◽  
Cost Effectiveness Analysis ◽  
Braf Mutations ◽  
Effectiveness Analysis

scholarly journals Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer

2012 ◽  
Vol 104 (23) ◽  
pp. 1785-1795 ◽  
Author(s):  
Ajay S. Behl ◽  
Katrina A. B. Goddard ◽  
Thomas J. Flottemesch ◽  
David Veenstra ◽  
Richard T. Meenan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Metastatic Colorectal Cancer ◽  
Cost Effectiveness Analysis ◽  
Braf Mutations ◽  
Effectiveness Analysis

scholarly journals Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis

2017 ◽  
Vol 22 (6) ◽  
pp. 694-699 ◽  
Author(s):  
Daniel A. Goldstein ◽  
Qiushi Chen ◽  
Turgay Ayer ◽  
Kelvin K. W. Chan ◽  
Kiran Virik ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Metastatic Colorectal Cancer ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis ◽  
Global Cost

Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 15090-15090
Author(s):  
M. Romeo ◽  
G. Soler ◽  
M. Martínez Villacampa ◽  
B. Laquente ◽  
A. López Doriga ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Metastatic Colorectal Cancer ◽  
Cost Effectiveness Analysis ◽  
Line Treatment ◽  
Effectiveness Analysis ◽  
Third Line ◽  
Third Line Treatment
Sign in / Sign up

Export Citation Format

Share Document